ReviewMaterials today. Bio2025
Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prebiotic-Empowered Probiotics with Gastrointestinal Stress Resistance for Enhanced Oral Therapy of Immunosuppression.Foods (Basel, Switzerland) · 2026Article
- The challenges and strategies for navigatingTheranostics · 2026Review
- Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) manifests as a chronic immune-mediated gastrointestinal disorder is characterized by multifactorial pathogenesis involving dysregulated immune responses and intestinal dysbiosis. This pathobiological interplay results in substantial impairment of patient quality of life while elevating colorectal carcinogenesis risk. Current therapeutic strategies primarily focus on inflammatory suppression and sustained remission, yet the clinical effectiveness is compromised by nonspecific biodistribution and systemic adverse events. Emerging evidence underscores the therapeutic potential of probiotics in preventing and treating IBD. Probiotics contribute to intestinal health by restoring microbial equilibrium, enhancing gut barrier function, and mitigating inflammation. Probiotics enhance immune function and stimulate the production of short-chain fatty acids (SCFAs), essential for intestinal health. However, the effectiveness of natural probiotics is often undermined by the harsh gastrointestinal environment, including poor gastric acid survival and weak mucosal adhesion, as well as physiological factors like oxidative stress from reactive oxygen species (ROS) and variable antibiotic exposure. To overcome these challenges, single-cell surface modification strategies have been developed to enhance probiotic functionality, stability, and targeted delivery. This review provides a comprehensive summary of recent advancements in probiotic surface modification technologies. It analyzes their classification, structural design, and functional attributes, systematically comparing physical, chemical, and biological strategies. This review also discusses the benefits, limitations, challenges, and future prospects of single-cell probiotic modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.